Industry Sponsored Studies

Currently Enrolling Studies

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated with Distal Sensory Polyneuropathy. 

The purpose of this research study is to learn more about LY3848575, a possible new investigational drug for the treatment of nerve pain. Dr. Gewandter is the site PI for this trial, with Dr. Annie Philip, Ms. Jacquie Behr, and Dr. Mark Williams serving as clinician Co-Is. Ms. Valerie Chiodo, Dr. Karim Saab, and Ms. Rachel DeGuzman are responsible for enrollment and study conduct. 

If you would like to know more about this study, please visit clinicaltrials.gov (https://clinicaltrials.gov/search?cond=distal%20sensory%20polyneuropathy&term=eli%20Lilly).  If you are interested in enrolling, please complete our interest survey here.

Previous Studies

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15%) in cancer survivors with painful chemotherapy-induced peripheral neuropathy (CIPN). (sponsored by Algo Therapeutix).

The purpose of this trial was to compare the efficacy of twice daily applications of ATX01 (10% & 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients. Dr. Gewandter was the site PI for this trial, with Dr. Annie Philip and Ms. Jacquie Behr serving as clinician Co-Is. Ms. Valerie Chiodo and Dr. Karim Saab were responsible for enrollment and study conduct.

If you would like to know more about this study, please visit clinicaltrials.gov.